

Tamlyn Anne Rautenberg

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4268849/publications.pdf>

Version: 2024-02-01

17
papers

82
citations

1684188

5
h-index

1474206

9
g-index

19
all docs

19
docs citations

19
times ranked

122
citing authors

#	ARTICLE	IF	CITATIONS
1	Whoâ€™s slipping through the cracks? A comprehensive individual, clinical and health system characterization of people with virological failure on firstâ€line HIV treatment in Uganda and South Africa. <i>HIV Medicine</i> , 2022, 23, 474-484.	2.2	5
2	Meta-analysis of health state utility values measured by EuroQol 5-dimensions (EQ5D) questionnaire in Chinese women with breast cancer. <i>BMC Cancer</i> , 2022, 22, 52.	2.6	4
3	Evaluating the cost utility of racecadotril in addition to oral rehydration solution versus oral rehydration solution alone for children with acute watery diarrhea in four low middle-income countries: Egypt, Morocco, Philippines and Vietnam. <i>Journal of Medical Economics</i> , 2022, 25, 274-281.	2.1	1
4	Resistance Testing for Management of HIV Virologic Failure in Sub-Saharan Africa. <i>Annals of Internal Medicine</i> , 2021, 174, 1683-1692.	3.9	9
5	Comparative analyses of published cost effectiveness models highlight critical considerations which are useful to inform development of new models. <i>Journal of Medical Economics</i> , 2020, 23, 221-227.	2.1	1
6	Health Economic Decision Tree Models of Diagnostics for Dummies: A Pictorial Primer. <i>Diagnostics</i> , 2020, 10, 158.	2.6	7
7	Cost utility, budget impact, and scenario analysis of racecadotril in addition to oral rehydration for acute diarrhea in children in Malaysia. <i>ClinicoEconomics and Outcomes Research</i> , 2018, Volume 10, 169-178.	1.9	7
8	The REVAMP trial to evaluate HIV resistance testing in sub-Saharan Africa: a case study in clinical trial design in resource limited settings to optimize effectiveness and cost effectiveness estimates. <i>HIV Clinical Trials</i> , 2017, 18, 149-155.	2.0	16
9	The cost utility and budget impact of adjuvant racecadotril for acute diarrhea in children in Thailand. <i>ClinicoEconomics and Outcomes Research</i> , 2017, Volume 9, 411-422.	1.9	5
10	Methods to construct a step-by-step beginner’s guide to decision analytic cost-effectiveness modeling. <i>ClinicoEconomics and Outcomes Research</i> , 2016, Volume 8, 573-581.	1.9	4
11	Economic outcomes of sequences which include monoclonal antibodies against vascular endothelial growth factor and/or epidermal growth factor receptor for the treatment of unresectable metastatic colorectal cancer. <i>Journal of Medical Economics</i> , 2014, 17, 99-110.	2.1	5
12	Letter to the Editor: Author Response. <i>Journal of Medical Economics</i> , 2014, 17, 443-443.	2.1	0
13	Economic Impact of Including Sequential Bevacizumab for the Treatment of Patients with Kirsten Ras Wild Type Unresectable Metastatic Colorectal Cancer in Four Latin American Countries. <i>Value in Health</i> , 2013, 16, A684.	0.3	0
14	PMD30 Short Term Health-Economic Outcomes of Continuous Subcutaneous Insulin Infusion (CSII) in Type 1 Diabetes: A Cost Comparison Analysis. <i>Value in Health</i> , 2012, 15, A350.	0.3	0
15	Evaluating the cost utility of racecadotril for the treatment of acute watery diarrhea in children: the RAWD model. <i>ClinicoEconomics and Outcomes Research</i> , 2012, 4, 109.	1.9	16
16	Cost analysis for cancer subgroups. <i>British Journal of Cancer</i> , 2009, 100, 1513-1513.	6.4	2
17	PCN129 FACTORS AFFECTING ADMINISTRATION REGIMES AND COSTS ASSOCIATED WITH EIGHT FIRST-LINE CHEMOTHERAPEUTIC DRUGS IN SEVEN COMBINATIONS, IN THE TREATMENT OF MNSCLC. <i>Value in Health</i> , 2009, 12, A281-A282.	0.3	0